The Evolving Role of Immunotherapy in NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Currently Approved Checkpoint Inhibitors

Second-Line Clinical Trial Design Patient Selection by Histology in CheckMate Trials

Second-Line Clinical Trial Design Highlights of KEYNOTE-010 Design

Second-Line Clinical Trial Design Inclusion of IC PD-L1 Staining in OAK

First-Line Monotherapy Trial Design Unexpected Differences in Outcomes

First-Line Monotherapy Trial Design Assessment of CheckMate 026

TMB as a Biomarker Data From CheckMate 026

First-Line Combination Therapy Rationale

First-Line Combination Therapy KEYNOTE-021 Cohort G

First-Line Combination Therapy KEYNOTE-189

First-Line Combination Therapy IMpower150 Efficacy

First-Line Combination Therapy IMpower150 Safety

Challenges of Biomarker Development

Concerns With First-Line Combination Regimens

Impact of Crossover in First-Line Combination Trials

Durvalumab Post Chemoradiotherapy in the PACIFIC Trial

Factors That Can Influence Toxicity Rates

Choosing an Appropriate Immunotherapy

Concluding Remarks

Abbreviations

Abbreviations (cont)